Abstract: Established Anthracyclines including Doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. However an effective and clinically applicable preventive treatment is yet to be discovered. Here we reported a 56-year-old female diagnosed stage IVB CD20 positive large B-cell Non-Hodgkin lymphoma developed doxorubicin cardiomyopathy after chemotherapy with a regimen of 5 drugs known as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) given for 5 cycles and intrathecal chemotherapy with 4 doses hydrocortison.

Anthracyclines, Cardiomyocytes, Doxorubicin